Mentions
Extended reach
Total likes
Video views
AI synopsis
In the discussions surrounding the publication, users share their personal experiences and professional recommendations regarding retinoids, stating things like, 'everyone I know with great skin use this' and that it has 'highly visible impact with minimal adverse effects.' These phrases, along with phrases emphasizing familiarity and satisfaction, exhibit a tone of endorsement and excitement, underscoring the publication's perceived significance in skincare.
Many posts convey a positive acknowledgment of the effectiveness of retinoids for skin aging, indicating general approval of the article's findings.
Discussion shows a strong curiosity about the results and implications of retinoids, particularly regarding their impact on skin health.
Some posts delve into specific experiences and recommendations related to retinoids, though not all discussions show deep analysis.
Several participants highlight the potential of retinoids to significantly influence dermatological practices and personal skin care routines.
So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submission system is owned by Elsevier, and more and more society journals are published by big commercial players (JBC a recent switch) https://t.co/uWwXqcCQRW
Credit where it's due - just submitted to a @wileyinresearch family journal: 20 minutes start to finish. Single (Word) upload, they extracted title, authors, affiliations, abstract, figures, & tables from; I only had to confirm This back end I think: https://t.co/im9Fq5hR8R https://t.co/1evSjYpPZY
2 - Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-48. doi: 10.2147/ciia.2006.1.4.327. PMID: 18046911; PMCID: PMC2699641. ->
We're joining forces with @manuscriptsapp to build the next-gen #opensource authoring platform for research. Read the @Atypon PR: https://t.co/JK8dnfiMhO Yes. We said OPEN SOURCE
@mededdoc Wiley Atypon Rex (AI-powered) already does this for authors. Free service for authors, paid for by journals. https://t.co/QS3yxSCrip Paperpal Preflight is a close competitor. @mededdoc
Atypon’s Founder and CEO, Georgios Papadopoulos steps down (remains Chairman). Marty Picco, Atypon’s SVP of Product, has been promoted to the new role of General Manager. https://t.co/TnPN7TIWDy
This review compares the efficacy and tolerability of the new double-conjugate retinoid cream, AHARet, to retinol and tretinoin for treating photoaging signs. The study shows AHARet effectively reduces fine lines…
The greatest skincare error is a routine that neglects the skin barrier. In today’s video, learn how to recognize stressed skin and support your skin barrier for better health. Discover effective solutions, including…
This video discusses why I advise against using The Ordinary's retinoids, including retinol and granactive retinoid. The brand has significantly changed skincare approaches, but their retinoids may not be the best…
This video examines the role of various retinoids, including tretinoin, in treating skin aging, which consists of both intrinsic and photoaging factors. Discover the advancements in drug delivery systems to enhance…
@Atypon Hi @Atypon, I'm interested in purchasing this Domain (https://t.co/9BihFL2SkI) for one of my community projects. The above domain has redirected to your website (https://t.co/u0cGbrMxbv), that's why I've sent this message.
@feminine_strong https://t.co/wf9933Td3W
why? - basically everyone I know with great skin (and bryan johnson) use this - derm said it's his easiest rec, highly visible impact with minimal adverse effects - extremely well researched (https://t.co/W52FHPWiwt)
@MarKes1900 @mus_nico @VUamsterdam @DanielTuijnman @pjvanerp @artinspector @onderwijsinsp @tweetsunl Ik heb geen ervaring met https://t.co/kzHs2SUCYR, het indiensysteem van https://t.co/TVGCf2fleE. Vermoedelijk moet indiener Ronald Meester bij iedere auteur een apart veld invullen voor naam, titel en affiliatie. RM zal verantwoordelijk zijn voor de juistheid van deze info.
@pjvanerp @mus_nico @VUamsterdam @DanielTuijnman @artinspector @onderwijsinsp @tweetsunl Voor zover mij bekend moet Ronald Meester, de indienende auteur, in dit systeem in aparte velden / hokjes de details invoeren over de namen, titels en affiliaties van alle auteurs en is Ronald Meester verantwoordelijk voor de juistheid van deze gegevens. https://t.co/kzHs2SUCYR
Yeah I saw that
Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety https://t.co/P7J6O5YYaW
If you or someone you know is thinking about suicide, call Talk Suicide Canada at 1-833-456-4566 (24/7), text at 45645 (4 p.m.–midnight ET), or visit https://t.co/9jWMIN9HC6. (Statistics Canada, 2022) https://t.co/s0T840hOoW (Lubin et al., 2010) https://t.co/AF8k4DaTJ8 [3/3]
#SustemicRACISM in a nutshell:⚡️⚡️ (Names/Pseudonyms of “Classes”#Objects
@mededdoc Wiley Atypon Rex (AI-powered) already does this for authors. Free service for authors, paid for by journals. https://t.co/QS3yxSCrip Paperpal Preflight is a close competitor. @mededdoc
2 - Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-48. doi: 10.2147/ciia.2006.1.4.327. PMID: 18046911; PMCID: PMC2699641. ->
#MobileFriendly site Atypon https://t.co/R8fTfWk0LP; more: Mobile Elegance https://t.co/oTxK5056lC
Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety https://t.co/Yi0rrnWycg
Почитала вчера про ретинол: ну ок, ретинол кажется действительно работает, если верить ОДНОМУ метаанализу 2006 года по 3 или 4 (!) исследованиям, все проведены до 2000 года (т.е. тупо в 90х). https://t.co/aCbtH4HeIT
Atypon by Wiley https://t.co/PitAQ47apl
RT @drpinky_tips: DOI: 10.2147/ciia.2006.1.4.327
RT @drpinky_tips: DOI: 10.2147/ciia.2006.1.4.327
RT @drpinky_tips: DOI: 10.2147/ciia.2006.1.4.327
RT @drpinky_tips: DOI: 10.2147/ciia.2006.1.4.327
DOI: 10.2147/ciia.2006.1.4.327
Atypon ReX - Atypon: Online Publishing Platform & Web Development Tools https://t.co/8MdFLEc35r This automated data extraction system for manuscript submission is pretty nice to work with (auto-detect the abstract, authors, affiliations, etc based on a Word file).
Credit where it's due - just submitted to a @wileyinresearch family journal: 20 minutes start to finish. Single (Word) upload, they extracted title, authors, affiliations, abstract, figures, & tables from; I only had to confirm This back end I think: https://t.co/im9Fq5hR8R https://t.co/1evSjYpPZY
If you’re wondering how… checkout Atypon’s very very long client list which includes American Chemical Society, AAAS journals, and MIT Press journals to name but a few. Through Atypon, Wiley have their finger in 50% of the STM publishing pie https://t.co/3btIWztQud https://t.co/Lr45AxcOL5
We are incredibly excited to welcome @Atypon to #ConTech2021 this year as a very welcome #SilverSponsor of the event. Read more on #Atypon here: https://t.co/gXfEjg05a3 Become a @ConTechLive sponsor or learn more here: https://t.co/r2ZGOJAdNE #EventSponsor #TechNews https://t.co/EyuztbVfuE
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
RT @cshperspectives: So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submi…
So Science now sits on a web platform owned by Wiley. They are not unique in that dependency of course: the PLOS submission system is owned by Elsevier, and more and more society journals are published by big commercial players (JBC a recent switch) https://t.co/uWwXqcCQRW
Check our presentation about how Access Innovations and @Atypon collaborate in order to provide a complete taxonomic workflow and to optimize #Literatum’s #taxonomy functionality toward improved #classification, #search and #discovery. https://t.co/l5ptCQYcpo
Support content discovery by downloading KBART files for @NEJM and @nejmcatalyst https://t.co/aIPsEXvbCX
RT @stokizane: 4月号の「情報の科学と技術」に書きますが、AtyponのManuscriptsは使えそうです。 https://t.co/sPSsKQETUM https://t.co/s9B5qW89Rm
The COVID-19 vaccine in pregnancy: risks benefits and recommendations [YMOB_13693.pdf (https://t.co/PXwYjDjojM) https://t.co/SEOfVxJTzG
Atypon: Online Publishing Platform & Web Development Tools https://t.co/2EzGN2IGH8
@AAAS, the world's largest general scientific society and publisher of the six Science family of journals, will be moving its full suite of online journal content to @Atypon online publishing platform, Literatum, in the summer of 2021 #scholcomm https://t.co/bQaG7pqb9m
Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety https://t.co/PJ6Gy3xb8S
Source: Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety by Siddharth Mukherjee, Abhijit Date, Vandana Patravale, Hans Christian Korting, Alexander Roeder, and Günther Weindl. https://t.co/Fyp5SNLDOP
Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety https://t.co/MQsK5BE3zC
Sounds great! Atypon Launches Manuscripts, a Collaborative Authoring Tool that Speeds Publication and Lets Researchers Integrate Code & Data. https://t.co/oh4DdXP2Wm
@Dmitri145 @rschon @NoFee_Science @pubreform Heres one funded only by a society: https://t.co/PwikrBEVEn
New social medialike service from Atypon announced - aims to allow users to follow research topics, citations, etc. https://www.atypon.com/news/atypon-launches-scitrus-an-ai-driven-discovery-tool-for-researchers/
Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety https://t.co/GTPEQrXx2S
RT @RickyPo: Atypon Acquires Inera, Developer of Editorial and XML Workflow Solutions for Scholarly, Technical, and Legal Publishers | Atyp…
RT @RickyPo: Atypon Acquires Inera, Developer of Editorial and XML Workflow Solutions for Scholarly, Technical, and Legal Publishers | Atyp…
See also: https://t.co/TDd0Hse0DM
See also: https://t.co/jc510ttJST
Atypon Acquires Inera, Developer of Editorial and XML Workflow Solutions for Scholarly, Technical, and Legal Publishers | Atypon: Online Publishing Platform & Web Development Tools https://t.co/UXy8H38ORh
RT @BillKasdorf: Big news is now public: @Atypon bought @Inera, maker of @eXtyles and related editorial software. https://t.co/0mapEm3tmB O…
RT @lisalibrarian: Consolidation continues in publishing workflow support .... https://t.co/zVXxBSzsDj
RT @BillKasdorf: Big news is now public: @Atypon bought @Inera, maker of @eXtyles and related editorial software. https://t.co/0mapEm3tmB O…
RT @BillKasdorf: Big news is now public: @Atypon bought @Inera, maker of @eXtyles and related editorial software. https://t.co/0mapEm3tmB O…
RT @BillKasdorf: Big news is now public: @Atypon bought @Inera, maker of @eXtyles and related editorial software. https://t.co/0mapEm3tmB O…
Big news is now public: @Atypon bought @Inera, maker of @eXtyles and related editorial software. https://t.co/0mapEm3tmB One of several recent @Atypon acquisitions--and in my view one of the best. Hope this is a win-win for both parties, and for scholarly publishing.
RT @lisalibrarian: Consolidation continues in publishing workflow support .... https://t.co/zVXxBSzsDj
Consolidation continues in publishing workflow support .... https://t.co/zVXxBSzsDj
@MOF_papers @Wiley_Chemistry @ChemEurJ @ChemAsianJ Please specify the feed URL. An "official" URL is eg: https://t.co/4WCBdVsXvT and should not contain https://t.co/2HRZhTUoVy URLs. It validates at https://t.co/W8ngJtb5sV - full URLs to papers are in the link or prism:url values, DOIs in prism:doi ;-)
Atypon Acquires RedLink®, the Data and Engagement Home for Scholarly Communications | Atypon: Online Publishing Platform & Web Development Tools https://t.co/jc510ttJST
https://t.co/SaQzZuVkQI https://t.co/Xg6qnCDZT1
Let's not forget who owns Atypon as we ponder this .... https://t.co/D9pEew64To
US government journal improves its UX and 508 compliance https://t.co/RlHPEt1iiJ
We're joining forces with @manuscriptsapp to build the next-gen #opensource authoring platform for research. Read the @Atypon PR: https://t.co/JK8dnfiMhO Yes. We said OPEN SOURCE
From @Atypon: "Atypon Acquires @authorea and Manuscripts..." This technology could help them move upstream in the workflow. The press release seems to address the first question: what kind of user base are they acquiring? https://t.co/3XhKjVBoGH
Wiley moves ahead in building out full researcher workflow support .... https://t.co/hViIEnO9qg
Atypon acquires two companies and prepares for Open Science: https://t.co/Nc6j4Y8k9a
Atypon Announces Leadership Transition https://t.co/88W54VnPX0
RT @mtclarke: Atypon’s Founder and CEO, Georgios Papadopoulos steps down (remains Chairman). Marty Picco, Atypon’s SVP of Product, has been…
RT @mtclarke: Atypon’s Founder and CEO, Georgios Papadopoulos steps down (remains Chairman). Marty Picco, Atypon’s SVP of Product, has been…
Atypon Announces Leadership Transition (Press Release) https://t.co/lQlAYdLC09
RT @mtclarke: Atypon’s Founder and CEO, Georgios Papadopoulos steps down (remains Chairman). Marty Picco, Atypon’s SVP of Product, has been…
Atypon’s Founder and CEO, Georgios Papadopoulos steps down (remains Chairman). Marty Picco, Atypon’s SVP of Product, has been promoted to the new role of General Manager. https://t.co/TnPN7TIWDy
For most clinicians, dabigatran will be perceived as the “anticoagulation for dummies” option [Pharmacotherapy] https://www.atypon.com/